Join medical experts as they discuss their approaches to identifying, treating, and managing rare diseases, like primary biliary cholangitis, neuroendocrine tumours, rare bone diseases, and growth disorders. The conversations also explore the evolving treatment landscape, including exciting innovations in gene therapies and the use of somatostatin analogues.
This independent medical education podcast is for HCPs with the ultimate goal of improving care for their patients. For more information, visit www.cor2ed.com
Think Narcolepsy: Why Early Recognition and Referral Matter
Join experts Dr Markus Schmidt and Dr Anna Heidbreder as they discuss the importance of early recognition and referral in narcolepsy type 1 (NT1), particularly as new targeted treatments begin to emerge.
Key discussion points include:
Emerging therapies: How OX2R agonists may transform narcolepsy care, with Phase 3 overporextin data showing significant improvements in wakefulness and cataplexy with no serious AEs reported.
Diagnostic red flags: Recognising excessive daytime sleepiness, cataplexy, sleep paralysis, and hallucinations to help reduce the current 7–10 year delay in diagnosis.
Clinical pitfalls: Avoiding common misdiagnoses, such as attributing symptoms to lifestyle-related fatigue in younger patients or sleep apnoea in older adults.
Specialist referral: The importance of timely referral for specialist assessment and objective sleep testing to support earlier access to emerging therapies.
By identifying these symptom clusters earlier, clinicians may improve long-term outcomes and quality of life for people living with NT1.
Key clinical takeaways:
New treatment options are emerging: OX2R agonists represent a shift toward targeting the underlying biology of NT1, with the potential to significantly improve patient outcomes
Early recognition is critical: Narcolepsy is often under-recognised and misdiagnosed, so clinicians should maintain a high index of suspicion, particularly in patients with excessive daytime sleepiness
Act early and refer appropriately: Timely referral to specialists is essential to confirm diagnosis, optimise management, and ensure patients can benefit from current and emerging therapies
You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/sleep-connect/programmes/narcolepsy-early-recognition-referral/?media=0
Or watch on YouTube: https://youtu.be/jHgORhjB_lw
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/sleep-connect/about/
X: https://x.com/SleepConnect_
Instagram: https://www.instagram.com/cor2edmeded
This content is intended for healthcare professionals only.
This podcast is supported by an Independent Education Grant from Takeda
This podcast is developed by cor2ed.com
Published May 2026
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
7 Nov 2025
Understanding EP-NEC: Through Diagnosis, Treatment, and Support
In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressive, and often misunderstood subset of neuroendocrine cancers.
They clarify the crucial differences between NETs and NECs, explain why accurate classification and rapid treatment are essential, and highlight current and emerging therapeutic approaches, including DLL3-targeted therapies.
Through both HCP and patient-centred perspectives, the conversation addresses real-world challenges, the importance of support networks, and the growing sense of hope for people affected by this difficult disease.
Key clinical takeaways:
Unlike NETs, EP-NECs are poorly-differentiated, high-grade, aggressive, and fast-growing cancers with, currently, a poor prognosis
While there remains a medical need for effective treatment of EP-NECs, clinical studies with DLL3-targeted agents show promise
Accessing a support network can provide emotional reinforcement and information for patients and their care partners
You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/net-connect/programmes/ep-nec-diagnosis-treatment-support/?media=0
Or watch on YouTube: https://youtu.be/nfng2s3jSw8
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true
X: https://x.com/net_connectinfo/status/1837039277353382012
This podcast is supported by an Independent Education Grant from ITM.
This podcast is developed by cor2ed.com
Published in November 2025
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
17 Sept 2025
Exploring the role of targeted radiopharmaceutical treatment in NETs
How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing, and safety?
In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in NETs.
As the conversation unfolds, the experts discuss evidence from recent studies, including the COMPETE trial, share practical insights on multidisciplinary decision-making, and highlight future directions such as the potential for first-line treatment with radioligand therapy.
Key clinical takeaways:
Pair the right patient with the right treatment using an understanding of the key clinical studies
The role of PRRT as a very effective 2nd-line treatment was consolidated by the COMPETE study data
The best outcomes are achieved through multi-disciplinary collaborations that include the patient
Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying transcript and infographic: https://cor2ed.com/net-connect/programmes/targeted-radiopharmaceutical-treatment-nets/?media=0
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true
X: https://x.com/net_connectinfo
This content is intended for healthcare professionals only.
This podcast is supported by an Independent Education Grant from ITM.
This podcast is developed by cor2ed.com
Published September 2025
Host of Rare Diseases Medical Conversation?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
